The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome

Hormone Molecular Biology and Clinical Investigation

Volumn 15, Issue 2, 2013, Pages 37-48

  Stimson, Roland H ^a   Walker, Brian R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

11 hydroxysteroid dehydrogenase type 1; Cortisol; Diabetes; Obesity; Tracer methodology

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; ANTIDIABETIC AGENT; CARBENOXOLONE; ENZYME INHIBITOR; HYDROCORTISONE; METFORMIN; TRACER; UNCLASSIFIED DRUG;

ADRENAL GLAND; ENZYME REGULATION; GENETIC MANIPULATION; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIVER; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE; STEROIDOGENESIS; SUBCUTANEOUS FAT; ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; GENETICS; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; METABOLIC SYNDROME X; OBESITY;

EID: 84915775144     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2013-0015     Document Type: Review

References (79)

1. Stewart PM, Valentino R, Wallace AM, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987;ii:821-4.
2. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess: a defect in the cortisolcortisone shuttle. J Clin Invest 1988;82:340-9. (Pubitemid 18262536)
3. Shimojo M, Ricketts ML, Petrelli MD, Moradi P, Johnson GD, Bradwell AR, Hewison M, Howie AJ, Stewart PM. Immunodetection of 11β-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization. Endocrinology 1997;138:1305-11. (Pubitemid 27089791)
4. Whorwood CB, Franklyn JA, Sheppard MC, Stewart PM. Tissue localization of 11β-hydroxysteroid dehydrogenase and its relationship to the glucocorticoid receptor. J Steroid Biochem 1992;41:21-8.
5. Seckl JR, Walker BR. 11β-Hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001;142:1371-6. (Pubitemid 32299662)
6. Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11β-Hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995;136:4754-61. (Pubitemid 3002167)
7. Atanasov AG, Nashev LG, Schweizer RA, Frick C, Odermatt A. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11β-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett 2004;571:129-33. (Pubitemid 38992936)
8. Kotelevtsev YV, Holmes MC, Burchell A, Houston PM, Scholl D, Jamieson PM, Best R, Brown RW, Edwards CR, Seckl JR, Mullins JJ. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycaemia on obesity and stress. Proc Natl Acad Sci USA 1997;94:14924-9. (Pubitemid 28041476)
9. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001;276:41293-300.
10. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-70. (Pubitemid 33150673)
11. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003;112:83-90. (Pubitemid 38056379)
12. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005;54:1023-31. (Pubitemid 40446315)
13. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004;101:7088-93. (Pubitemid 38596447)
14. Lavery GG, Zielinska AE, Gathercole LL, Hughes B, Semjonous N, Guest P, Saqib K, Sherlock M, Reynolds G, Morgan SA, Tomlinson JW, Walker EA, Rabbitt EH, Stewart PM. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 2012;153:3236-48.
15. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 1997;349:1210-3. (Pubitemid 27190044)
16. Andrew R, Phillips DI, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998;83:1806-9. (Pubitemid 28501063)
17. Andrews RC, Herlihy O, Livingstone DE, Andrew R, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab 2002;87:5587-93. (Pubitemid 36034364)
18. Johnstone AM, Faber P, Andrew R, Gibney ER, Elia M, Lobley G, Stubbs RJ, Walker BR. Influence of short-term dietary weight loss on cortisol secretion and metabolism in obese men. Eur J Endocrinol 2004;150:185-94. (Pubitemid 38312811)
19. Andrew R, Smith K, Jones GC, Walker BR. Distinguishing the activities of 11β-hydroxysteroid dehydrogenases in vivo using isotopically labelled cortisol. J Clin Endocrinol Metab 2002;87:277-85. (Pubitemid 34084702)
20. Andrew R, Westerbacka J, Wahren J, Yki-Jarvinen H, Walker BR. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 2005;54:1364-70. (Pubitemid 40586665)
21. Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson CM, Toffolo G, Cobelli C, Rizza RA. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-β hydroxysteroid dehydrogenase (11β-HSD) type 1 pathway. Diabetes 2004;53:2051-9. (Pubitemid 38970754)
22. Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC, Loriaux DL. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991;72:39-45. (Pubitemid 21921653)
23. Stimson RH, Andrew R, McAvoy NC, Tripathi D, Hayes PC, Walker BR. Increased whole-body and sustained liver cortisol regeneration by 11β-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 2011;60:720-5.
24. Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson MC, Toffolo G, Cobelli C, Rizza RA. Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab 2005;90:3919-26. (Pubitemid 41058152)
25. Basu R, Basu A, Grudzien M, Jung P, Jacobson P, Johnson M, Singh R, Sarr M, Rizza RA. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 2009;58:39-45.
26. Stimson RH, Andersson J, Andrew R, Redhead DN, Karpe F, Hayes PC, Olsson T, Walker BR. Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009;58:46-53.
27. Hughes KA, Manolopoulos KN, Iqbal J, Cruden NL, Stimson RH, Reynolds RM, Newby DE, Andrew R, Karpe F, Walker BR. Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose, and skeletal muscle tissues in vivo. Diabetes 2012;61:1357-64.
28. Hellman L, Nakada F, Zumoff B, Fukushima D, Bradlow HL, Gallacher TF. Renal capture and oxidation of cortisol in man. J Clin Endocrinol 1971;33:52-62.
29. Whitworth JA, Stewart PM, Burt D, Atherden SM, Edwards CR. The kidney is the major site of cortisone production in man. Clin Endocrinol (Oxf) 1989;31:355-61. (Pubitemid 19219243)
30. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC, Sharma AM. Regulation of 11β-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 2004;12:9-17. (Pubitemid 41137482)
31. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002;51:1066-75.
32. Wake DJ, Homer NZ, Andrew R, Walker BR. Acute in vivo regulation of 11β-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans. J Clin Endocrinol Metab 2006;91:4682-8. (Pubitemid 44833457)
33. Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, Shackleton CH, Parker KL, White PC, Stewart PM. Hexose-6-phosphate dehydrogenase knock-out mice lack 11β-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 2006;281:6546-51. (Pubitemid 43847588)
34. Lavery GG, Walker EA, Tiganescu A, Ride JP, Shackleton CH, Tomlinson JW, Connell JM, Ray DW, Biason-Lauber A, Malunowicz EM, Arlt W, Stewart PM. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 2008;93:3827-32.
35. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86:1418-21. (Pubitemid 32323037)
36. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999;33:1364-8. (Pubitemid 29282655)
37. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005;54:872-9. (Pubitemid 40322093)
38. Livingstone DE, Jones GC, Smith K, Andrew R, Kenyon CJ, Walker BR. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000;141:560-3. (Pubitemid 32250479)
39. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002;87:3330-6. (Pubitemid 34816385)
40. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisonecortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999;84:1022-7.
41. Baudrand R, Carvajal CA, Riquelme A, Morales M, Solis N, Pizarro M, Escalona A, Boza C, Perez G, Dominguez A, Arrese M, Fardella CE. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. Obes Surg 2010;20:77-83.
42. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002;87:2701-5. (Pubitemid 34655333)
43. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA, Tataranni PA, Walker BR. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003;88:2738-44. (Pubitemid 36724450)
44. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T, Walker BR. Local and systemic impact of transcriptional upregulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 2003;88:3983-8. (Pubitemid 37034555)
45. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002;87:5630-5. (Pubitemid 36034370)
46. Goedecke JH, Wake DJ, Levitt NS, Lambert EV, Collins MR, Morton NM, Andrew R, Seckl JR, Walker BR. Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol (Oxf) 2006;65:81-7.
47. Desbriere R, Vuaroqueaux V, Achard V, Boullu-Ciocca S, Labuhn M, Dutour A, Grino M. 11β-Hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 2006;14:794-8. (Pubitemid 46219720)
48. Michailidou Z, Jensen MD, Dumesic DA, Chapman KE, Seckl JR, Walker BR, Morton NM. Omental 11β-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring) 2007;15:1155-63. (Pubitemid 46932470)
49. Mariniello B, Ronconi V, Rilli S, Bernante P, Boscaro M, Mantero F, Giacchetti G. Adipose tissue 11β-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol 2006;155:435-41. (Pubitemid 44463950)
50. Leyvraz C, Verdumo C, Suter M, Paroz A, Calmes JM, Marques-Vidal PM, Giusti V. Changes in gene expression profile in human subcutaneous adipose tissue during significant weight loss. Obes Facts 2012;5:440-51.
51. Torrecilla E, Fernandez-Vazquez G, Vicent D, Sanchez-Franco F, Barabash A, Cabrerizo L, Sanchez-Pernaute A, Torres AJ, Rubio M.A. Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes Surg 2012;22:478-86.
52. Koistinen HA, Forsgren M, Wallberg-Henriksson H, Zierath JR. Insulin action on expression of novel adipose genes in healthy and type 2 diabetic subjects. Obes Res 2004;12:25-31. (Pubitemid 41137484)
53. Sjostrand M, Jansson PA, Palming J, de Schoolmeester J, Gill D, Rees A, Sjogren L, Persson T, Eriksson JW. Repeated measurements of 11β-HSD-1 activity in subcutaneous adipose tissue from lean, abdominally obese, and type 2 diabetes subjects-no change following a mixed meal. Horm Metab Res 2010;42:798-802.
54. Nair S, Lee YH, Lindsay RS, Walker BR, Tataranni PA, Bogardus C, Baier LJ, Permana PA. 11β-Hydroxysteroid dehydrogenase type 1: genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 2004;47:1088-95. (Pubitemid 38918169)
55. Olza J, Gil-Campos M, Leis R, Ruperez AI, Tojo R, Canete R, Gil A, Aguilera CM. A gene variant of 11β-hydroxysteroid dehydrogenase type 1 is associated with obesity in children. Int J Obes (Lond) 2012;36:1558-63.
56. Gambineri A, Tomassoni F, Munarini A, Stimson RH, Mioni R, Pagotto U, Chapman KE, Andrew R, Mantovani V, Pasquali R, Walker BR. A combination of polymorphisms in HSD11B1 associates with in vivo 11β-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur J Endocrinol 2011;165:283-92.
57. Smit P, Dekker MJ, de Jong FJ, van den Beld AW, Koper JW, Pols HA, Brinkmann AO, de Jong FH, Breteler MM, Lamberts SW. Lack of association of the 11β-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia. J Clin Endocrinol Metab 2007;92:359-62. (Pubitemid 46067553)
58. Moon SS, Lee YS, Kim JG, Kim SW, Jeong JY, Jeon EJ, Seo HA, Kwak SH, Park KS, Lee IK. Relationship of 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase gene polymorphisms with metabolic syndrome and type 2 diabetes. Endocr J 2011;58:949-59.
59. Stimson RH, Johnstone AM, Homer NZ, Wake DJ, Morton NM, Andrew R, Lobley GE, Walker BR. Dietary macronutrient content alters cortisol metabolism independently of body weight changes in obese men. J Clin Endocrinol Metab 2007;92:4480-4. (Pubitemid 350074774)
60. Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L, Stewart PM. Weight loss increases 11β-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J Clin Endocrinol Metab 2004;89:2711-6. (Pubitemid 38766354)
61. Purnell JQ, Kahn SE, Samuels MH, Brandon D, Loriaux DL, Brunzell JD. Enhanced cortisol production rates, free cortisol, and 11β-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. Am J Physiol Endocrinol Metab 2009;296:E351-7.
62. Karlsson C, Jernas M, Olsson B, Lystig T, Gummesson A, Storlien L, Groop L, Carlsson B. Differences in associations between HSD11B1 gene expression and metabolic parameters in subjects with and without impaired glucose homeostasis. Diabetes Res Clin Pract 2010;88:252-8.
63. Simonyte K, Olsson T, Naslund I, Angelhed JE, Lonn L, Mattsson C, Rask E. Weight loss after gastric bypass surgery in women is followed by a metabolically favorable decrease in 11β-hydroxysteroid dehydrogenase 1 expression in subcutaneous adipose tissue. J Clin Endocrinol Metab 2010;95:3527-31.
64. Basu R, Singh R, Basu A, Johnson CM, Rizza RA. Effect of nutrient ingestion on total-body and splanchnic cortisol production in humans. Diabetes 2006;55:667-74. (Pubitemid 43343222)
65. Mai K, Kullmann V, Bobbert T, Maser-Gluth C, Mohlig M, Bahr V, Pfeiffer AF, Spranger J, Diederich S. In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance. Clin Endocrinol (Oxf) 2005;63:442-9. (Pubitemid 41442339)
66. Mai K, Andres J, Bobbert T, Maser-Gluth C, Mohlig M, Bahr V, Pfeiffer AF, Spranger J, Diederich S. Rosiglitazone decreases 11β-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue. Clin Endocrinol (Oxf) 2007;67:419-25. (Pubitemid 47283841)
67. Wake DJ, Stimson RH, Tan GD, Homer NZ, Andrew R, Karpe F, Walker BR. Effects of peroxisome proliferator-activated receptor (PPAR) α and γ agonists on 11β-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. J Clin Endocrinol Metab 2007;92:1848-56. (Pubitemid 46997199)
68. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998;391:79-82. (Pubitemid 28079218)
69. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL,Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808. (Pubitemid 38063703)
70. Sutinen J, Kannisto K, Korsheninnikova E, Nyman T, Ehrenborg E, Andrew R, Wake DJ, Hamsten A, Walker BR, Yki-Jarvinen H. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004;47:1668-71. (Pubitemid 40022399)
71. Nixon M, Wake DJ, Livingstone DE, Stimson RH, Esteves CL, Seckl JR, Chapman KE, Andrew R, Walker BR. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes 2012;61:790-6.
72. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995;80:3155-9.
73. Wang SJ, Birtles S, de Schoolmeester J, Swales J, Moody G, Hislop D, O'Dowd J, Smith DM, Turnbull AV, Arch JR. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 2006;49:1333-7.
74. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li ZH, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu TJ, Xiao JY, Zhang BB, Wright SD, Thieringer R. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005;202:517-27. (Pubitemid 41186950)
75. Kipari T, Hadoke PW, Iqbal J, Man TY, Miller E, Coutinho AE, Zhang Z, Sullivan KM, Mitic T, Livingstone DE, Schrecker C, Samuel K, White CI, Bouhlel MA, Chinetti-Gbaguidi G, Staels B, Andrew R, Walker BR, Savill JS, Chapman KE, Seckl JR. 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. FASEB J 2013;27:1519-31.
76. Garcia RA, Search DJ, Lupisella JA, Ostrowski J, Guan B, Chen J, Yang WP, Truong A, He A, Zhang R, Yan M, Hellings SE, Gargalovic PS, Ryan CS, Watson LM, Langish RA, Shipkova PA, Carson NL, Taylor JR, Yang R, Psaltis GC, Harrity TW, Robl JA, Gordon DA. 11β-Hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE-/-mice. PLoS ONE 8:e53192, 2013.
77. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R. The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010;33:1516-22.
78. Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E, Kaufman KD. Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 2011;13:498-504.
79. Lawson AJ, Walker EA, Lavery GG, Bujalska IJ, Hughes B, Arlt W, Stewart PM, Ride JP. Cortisone-reductase deficiency associated with heterozygous mutations in 11β-hydroxysteroid dehydrogenase type 1. Proc Natl Acad Sci USA 2011;108:4111-6.